Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
Saved in:
| Title: | Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression. |
|---|---|
| Authors: | Rivera FB; Department of Medicine, Lincoln Medical Center, New York, NY, USA., Cha SW; Cebu Institute of Medicine, Cebu City, Philippines., Magalong JV; College of Medicine, San Beda University, Manila, Philippines., Bantayan NRB; University of the Philippines College of Medicine, Manila, Philippines., Cruz LLA; University of the Philippines College of Medicine, Manila, Philippines., Arias-Aguirre E; Cebu Institute of Medicine, Cebu City, Philippines., Aguirre Z; Cebu Institute of Medicine, Cebu City, Philippines., Varona MC; Cebu Institute of Medicine, Cebu City, Philippines., Co EMF; Cebu Institute of Medicine, Cebu City, Philippines., Lumbang GNO; Cebu Institute of Medicine, Cebu City, Philippines., Enkhmaa B; Division of Endocrinology, Diabetes & Metabolism, UC Davis Health, Davis, CA, USA. |
| Source: | Current medical research and opinion [Curr Med Res Opin] 2024 Jul; Vol. 40 (7), pp. 1103-1121. Date of Electronic Publication: 2024 Jun 11. |
| Publication Type: | Journal Article; Meta-Analysis |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38836510 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Rivera+FB%22">Rivera FB</searchLink>; Department of Medicine, Lincoln Medical Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Cha+SW%22">Cha SW</searchLink>; Cebu Institute of Medicine, Cebu City, Philippines.<br /><searchLink fieldCode="AU" term="%22Magalong+JV%22">Magalong JV</searchLink>; College of Medicine, San Beda University, Manila, Philippines.<br /><searchLink fieldCode="AU" term="%22Bantayan+NRB%22">Bantayan NRB</searchLink>; University of the Philippines College of Medicine, Manila, Philippines.<br /><searchLink fieldCode="AU" term="%22Cruz+LLA%22">Cruz LLA</searchLink>; University of the Philippines College of Medicine, Manila, Philippines.<br /><searchLink fieldCode="AU" term="%22Arias-Aguirre+E%22">Arias-Aguirre E</searchLink>; Cebu Institute of Medicine, Cebu City, Philippines.<br /><searchLink fieldCode="AU" term="%22Aguirre+Z%22">Aguirre Z</searchLink>; Cebu Institute of Medicine, Cebu City, Philippines.<br /><searchLink fieldCode="AU" term="%22Varona+MC%22">Varona MC</searchLink>; Cebu Institute of Medicine, Cebu City, Philippines.<br /><searchLink fieldCode="AU" term="%22Co+EMF%22">Co EMF</searchLink>; Cebu Institute of Medicine, Cebu City, Philippines.<br /><searchLink fieldCode="AU" term="%22Lumbang+GNO%22">Lumbang GNO</searchLink>; Cebu Institute of Medicine, Cebu City, Philippines.<br /><searchLink fieldCode="AU" term="%22Enkhmaa+B%22">Enkhmaa B</searchLink>; Division of Endocrinology, Diabetes & Metabolism, UC Davis Health, Davis, CA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%220351014%22">Current medical research and opinion</searchLink> [Curr Med Res Opin] 2024 Jul; Vol. 40 (7), pp. 1103-1121. <i>Date of Electronic Publication: </i>2024 Jun 11. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Meta-Analysis – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Informa+Healthcare%22">Informa Healthcare </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>0351014 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1473-4877 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2203007995%22">03007995 </searchLink><i>NLM ISO Abbreviation: </i>Curr Med Res Opin <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38836510 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/03007995.2024.2363971 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1103 Titles: – TitleFull: Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Rivera FB – PersonEntity: Name: NameFull: Cha SW – PersonEntity: Name: NameFull: Magalong JV – PersonEntity: Name: NameFull: Bantayan NRB – PersonEntity: Name: NameFull: Cruz LLA – PersonEntity: Name: NameFull: Arias-Aguirre E – PersonEntity: Name: NameFull: Aguirre Z – PersonEntity: Name: NameFull: Varona MC – PersonEntity: Name: NameFull: Co EMF – PersonEntity: Name: NameFull: Lumbang GNO – PersonEntity: Name: NameFull: Enkhmaa B IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 07 Text: 2024 Jul Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 1473-4877 Numbering: – Type: volume Value: 40 – Type: issue Value: 7 Titles: – TitleFull: Current medical research and opinion Type: main |
| ResultId | 1 |